1. - Allergika

Business Opportunity in
Dermatology
ALLERGIKA Pharma GmbH
Information Memorandum
for International Cooperation
I. ALLERGIKA Profile
In 1991 ALLERGIKA Pharma GmbH was founded as a privately owned German pharmaceutical
company based near Munich. ALLERGIKA is the leading company of Anti Dust Mite Products in
Germany.
The name ALLERGIKA® is one of the main assets of the company and represents a
unique program:

ALLERGIKA® stands for the company

ALLERGIKA® stands for the umbrella trademark

ALLERGIKA® stands for the products

ALLERGIKA® stands for the product indications and applications

ALLERGIKA® is identification for the patients
The ALLERGIKA® trademark is registered worldwide.
ALLERGIKA employees 60 people, thereof 20 sales reps for dermatologists, pediatricians and
pharmacies, one key account manager hospital and one key account manager pharmacy. The
company’s total sales is approximately 6 Mio. EUR.
In 2006 ALLERGIKA has started with the development, marketing and distribution of its
dermatological products, so called ALLERGIKA® Therapeutic Skin Care Line.
ALLERGIKA® TSC Line is one of the most successful dermatological OTC product lines in
Germany with an increasing rate of more than 30% in total and up to 200% per product.
ALLERGIKA® TSC Products have a distribution rate of more than 20% in German pharmacies.
Chart 1: Successful sales development of the ALLERGIKA® TSC Line
2
I. ALLERGIKA Profile
ALLERGIKA® Therapeutic Skin Care (TSC) Line is clearly positioned in the field of
skin diseases. The name ALLERGIKA® Therapeutic Skin Care underlines the positioning
close to the dermatological therapy.
Chart 2: Positioning of the ALLERGIKA® TSC Line
The promotion of ALLERGIKA® TSC Line is focused on dermatologists and pediatricians
in private offices and hospitals. ALLERGIKA promotes and sells its ALLERGIKA ® TSC
Products exclusively to pharmacies (franchise business) and via wholesalers to
pharmacies.
ALLERGIKA® Therapeutic Skin Care is very well acknowledged and accepted by doctors
and pharmacists as well as patients.
ALLERGIKA® Eyelid Cream ranks No.1 in its market segment in
Germany! ALLERGIKA® Lipolotio Urea 5% ranks already 3rd on
the German market! Both products belong to the top selling products.
No.1
Since 2008 ALLERGIKA has started to internationalize its
ALLERGIKA® Therapeutic Skin Care products with the
successful launch in Austria, Hungary, Luxemburg, Morocco
and Saudi Arabia.
3
II. ALLERGIKA Market
All over the world more than 30% of the population is affected by allergies with
an increasing tendency up to 50% in the next twenty years.
Allergies are quite often a multimorbide occurance. They are characterized by
the so called “Atopic March”.
Chart 3: Distribution of allergic diseases in Europe (Source: WHO 2005)
Allergic Skin that means skin diseases related with eczema (e.g. neurodermatitis and
contact eczema) with a distribution rate of 13% are the most frequent allergic disease
worldwide!
Chart 4: Distribution of Allergic Diseases (Source: ISAAC, uniklinikum-giessen.de, 2008)
Dry skin is the main symptom of many skin diseases. More than 25% of the
population worldwide are suffering on dry skin. They are also a target for
ALLERGIKA® TSC Line.
4
III. ALLERGIKA Basic Therapy of
Eczema and Dry Skin
Skin diseases are diagnosed and treated in the first instance by dermatologists and pediatricians
in private practices and hospitals.
In the International Guideline for the treatment and prevention of eczema and dry skin of the
European Academy of Dermatology and Venereology (EADV 2013) the Basic Therapy with
emollients and cleansing products plays an important role and are recommended or prescribed
by dermatologists complementary to their therapy with steroids, antibiotics or antiseptics.
The requirements for the Basic Therapy according to the International Guideline are as follows:
1. Allergen Avoidance
2. Active Ingredients
3. Medical Galenic Formulation
ALLERGIKA® Therapeutic Skin Care Products fulfill the strict requirements of the
International Guideline and is therefore the ideal partner for the dermatological therapy.
ALLERGIKA® helps to reduce pharmaceuticals like steroids.
Chart 5: International Guidelines for treatment of atopic eczema and dry skin to graded severity (EADV 2013)
5
IV. ALLERGIKA Therapeutic Skin Care:
Summary of ALLERGIKA´s USPs
1. ALLERGIKA has developed together with international key opinion leaders
four ALLERGIKA® Therapeutic Concepts “from top to toe” for allergic patients:
Concept I:
Concept II:
Concept III:
Concept IV:
Sensitive and atopic skin
Dry skin
Sensitive atopic and dry skin of Baby & Kids
Sun intolerance
ALLERGIKA offers with these concepts the only and most comprehensive program especially
for allergic patients on the market.
2.
ALLERGIKA® offers with Dermifant® the only skin care concept for babies and kids from
“First Day”.
3.
ALLERGIKA® TSC Line is consequently produced
- 100% free of perfumes, preservatives (also parabens) and dyes
- 100% free of natural allergens
- 100% free of the 328 most frequent allergens as listed by the
German Contact Dermatitis Group
4.
ALLERGIKA® Therapeutic Skin Care Products are produced exclusively in
Germany in pharmaceutical quality.
5.
ALLERGIKA® Therapeutic Skin Care Products are clinically tested on atopic
skin with very high skin tolerance.
6.
ALLERGIKA® Therapeutic Skin Care Products are used and recommended
by leading German dermatological hospitals.
6
IV. ALLERGIKA Therapeutic Skin Care:
Product Overview
Chart 6: ALLERGIKA® Therapeutic Skin Care Program (The ALLERGIKA® Core Products are highlighted in red)
Concept I
Concept II
Concept III
Concept IV
.
7
V. ALLERGIKA® Core Products for the main
dermatological indications
ALLERGIKA offers the ideal Basic Therapy for the dermatological treatment of eczema and dry
skin according to the International Guideline. In the following table the main dermatological
indications from top to toe are pointed out. ALLERGIKA can provide for each indication a
suitable product.
These products are the ALLERGIKA® Core Products which are mostly recommended
and/or prescribed by dermatologists.
Nevertheless the allergic patient need a whole program which should be provided by the
pharmacy (Chart 6).
Chart 7: ALLERGIKA® Core Products for the main dermatological indications
(Recommendation by Prof. Enk, University of Heidelberg)
Pos.
Localisation
Main dermatological
Indication
ALLERGIKA® Core Products
for Basic Therapy
1
Scalp / Hair
Scalp eczema, Seborrhoic eczema
ALLERGIKA® Mild Shampoo
2
Eyelid
Periorbital dermatitis, Eyelid eczema,
Airborne dermatitis
ALLERGIKA® Eyelid Cream
3
Local areas
Subacute eczema
ALLERGIKA® Primrose Oil Cream 20%
4
Face
Sebostasis
ALLERGIKA® Facial Cream Urea 5%
5
Hand
Fissured chronic hand eczema,
psoriasis palmaris
ALLERGIKA® Cream Urea 5%
6
Hand
(Atopic) hand eczema
ALLERGIKA® Soft Hand Cream
7
Body
Sebostasis,mild atopic eczema
ALLERGIKA® Lipolotio Urea 5%
8
Body
Dehydration eczema, xerosis,
diabetic skin
ALLERGIKA® Lipolotio Urea 5%F
9
Body
Psoriasis, Ichthyosis
ALLERGIKA® Lipolotio Urea 10%
10
Body
Sensitive, atopic skin prone to
redness and acute itching
ALLERGIKA® Hydrolotio Sensitive
11
Body
Sensitive, atopic skin and chronic
eczema
ALLERGIKA® Lipolotio Sensitive
12
Body
Sensitive, atopic skin
ALLERGIKA® Bath & Shower Gel Mild
8
VI. ALLERGIKA TSC Line:
Regulatory Affairs
1. ALLERGIKA Pharma GmbH is a pharmaceutical company
certificated according to QMS ISO 9001:2000.
2. In respect to the regulatory requirements ALLERGIKA® Therapeutic Skin
Care products are defined as cosmetics according to the European
Cosmetic Directive 1223/2009 valid in all EU countries. ALLERGIKA®
products are registered in all EU countries via CPNP procedure.
3. In countries outside the EU similar registration requirements exist. For this
purpose ALLERGIKA can provide a comprehensive product documentation:
•
•
•
•
•
Technical record
Stability data
Preservation challenge tests
Skin tolerance tests even on atopic skin
Safety reports
4. Registration of ALLERGIKA® Therapeutic Skin Care may take 3-7 months
depending on the country outside the EU.
9
VII. ALLERGIKA TSC Line:
Clinical Documentation
ALLERGIKA® Therapeutic Skin Care products are excellent documented !
1. The therapeutical efficacy of all main active ingredients like Urea, Glycerol,
Evening Primrose oil, Polidocanol, Allantoin and Bisabolol haven been
proven. They are dermatological recommended and clinically documented.
2. All products have been tested on atopic skin with excellent results.
3. For all core products clinical trials with at least 20 patients on atopic skin
over 4 weeks demonstrate excellent therapeutical results.
4. Clinical trials of ALLERGIKA® Basic cream and ointment (pharmaceuticals with German
registration) in the interval therapy of eczema with steroids prove the clinical efficacy and
steroid sparing effect.
5. Clinical trials of ALLERGIKA® Eyelid cream and Lipolotio urea 5% are still going on
(27 patients over 4 weeks; barrier effect).
6. Comprehensive clinical documentation is available.
7. ALLERGIKA® Therapeutic Skin Care products are used and recommended
from leading dermatological hospitals in Germany since nearly 10 years.
10
VIII. ALLERGIKA TSC Line:
International Business Opportunity
The ALLERGIKA® Therapeutic Skin Care product portfolio by its nature is based on the
prescription and/or recommendation by doctors and pharmacists.
ALLERGIKA® Therapeutic Skin Care is doctor and pharmacy oriented.
It is part of the dermatological therapy of doctors.
As a consequence the ALLERGIKA® Therapeutic Skin Care program should be promoted
to dermatologists, pediatricians in private offices and in hospitals in the first instance.
It is the strategic objective of ALLERGIKA Pharma GmbH to internationalize its unique
ALLERGIKA® Therapeutic Skin Care program with regional and/or national partners all over the
world.
ALLERGIKA Pharma GmbH is looking for cooperation partners to which ALLERGIKA®
Therapeutic Skin Care may be synergistic or complementary to its existing product portfolio
(e.g. topical steroids) and/or an option for a future company strategy.
ALLERGIKA Pharma GmbH offers:
1. A sustainable, long term business opportunity in a big and fast growing market
2. Unique ALLERGIKA® program with a worldwide registered trademark
3. High Quality products „Made in Germany“
4. Exklusive, long term Distribution Agreement with attractive margins
5. Advertising, promotion and sales force training support
11
VIV. Coordinates
In the event that you consider ALLERGIKA® Therapeutic Skin Care as an alternative
business opportunity and/or a strategic company option, please contact ALLERGIKA Pharma
GmbH as follows:
Mr. Hartmut Bannert, President, CEO
email: [email protected]. Mobile: +49 172 985 1406
Mrs. Stefanie Edler, Business Development Manager
email: [email protected]. Mobile: +49 177 915 4401
ALLERGIKA Pharma GmbH, Bürgermeister-Seidl-Str.8
D-82515 Wolfratshausen / Germany
phone +49 81 71 42 25 7
fax +49 81 71 42 25 82 4
www.allergika.de
[email protected]
12